


Amendments to the claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:


- R_1 is halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy or halo C_{1-6} alkyl;
- m is 0, 1, 2, 3 or 4;
- X is N or CH;
- R_2 is halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy or halo C_{1-6} alkyl;
- n is 0, 1 or 2;
- W is $-CH_2-$, $-CH(C_{1-6}alkyl)-$ or $-C(C_{1-6}alkyl)(C_{1-6}alkyl)-$;
- p is 0, 1, 2 or 3;
- Y and Z together form a C_{3-7} cycloalkylene group, or Y is $-CH_2-$, $-CH(C_{1-6}alkyl)-$ or $-C(C_{1-6}alkyl)(C_{1-6}alkyl)-$ and Z is $-CH_2-$, $-CHOH-$, $-CHR_6-$ or $-CR_6R_7-$ (wherein R_6 and R_7 are independently halogen, cyano, C_{1-6} alkyl or C_{1-6} alkoxy);
- R_3 and R_4 are independently hydrogen, C_{1-6} alkyl, C_{1-6} alkylsulfonyl or a group having the formula (II):



wherein


- r is 0, 1, 2, 3 or 4;

- A is oxygen or sulfur;
 - B is a single bond or $\text{-NR}_8\text{-}$ (wherein R_8 is hydrogen, C_{1-6} alkyl or aryl, wherein the aryl is optionally substituted by one or more substituents independently selected from halogen, oxo, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl, and C_{1-6} alkoxy);
 - D is $\text{-(CH}_2\text{)}_t\text{-}$, $\text{-(CH}_2\text{)}_t\text{O-}$ or $\text{-O(CH}_2\text{)}_t\text{-}$, wherein t is 0, 1, 2, 3 or 4; and
 - E is C_{1-6} alkyl, halo C_{1-6} alkyl, C_{3-7} cycloalkyl (optionally substituted by one or more substituents independently selected from halogen, hydroxy, oxo, C_{1-6} alkyl, cyano, CF_3 , OCF_3 , C_{1-6} alkoxy and C_{1-6} alkanoyl), aryl (optionally substituted by one or more substituents independently selected from halogen, oxo, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl and C_{1-6} alkoxy), or E is $\text{-NR}_9\text{R}_{10}$, wherein R_9 and R_{10} are independently selected from hydrogen, C_{1-6} alkyl and aryl (optionally substituted by one or more substituents independently selected from halogen, oxo, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl and C_{1-6} alkoxy);
- or R_3 and R_4 , together with the nitrogen atom to which R_3 and R_4 are attached, form a 3-7 membered monocyclic heterocyclic group or a 8-11 membered bicyclic heterocyclic group, wherein each group is optionally substituted by one or more substituents selected from halogen, oxo, C_{1-6} alkyl, cyano, CF_3 , C_{1-6} alkoxy, C_{1-6} alkanoyl, aryl and aryl C_{1-6} alkyl (wherein the aryl and the aryl C_{1-6} alkyl are further optionally substituted by one or more halogen, oxo, C_{1-6} alkyl, cyano, CF_3 , C_{1-6} alkoxy or C_{1-6} alkanoyl); and
 - R_5 is independently halogen, cyano, C_{1-6} alkyl or C_{1-6} alkoxy; and
 - q is 0, 1, 2, 3 or 4.
2. (original) A compound as claimed in claim 1, wherein n is 0 or n is 1 and R_2 is C_{1-6} alkyl.
3. (currently amended) A compound as claimed in claim 1 ~~or claim 2~~, wherein p is 0.
4. (currently amended) A compound as claimed in claim 1, ~~2 or 3~~, wherein Y and Z are independently $\text{-CH}_2\text{-}$, $\text{-CH(CH}_3\text{)-}$ or -CH(OH)- .
5. (currently amended) A compound as claimed in claim 1 ~~any of claims 1-4~~, wherein formula (II) is:



wherein A is oxygen or sulfur, D is $-(CH_2)_t-$, $-(CH_2)_tO-$ or $-O(CH_2)_t-$, wherein t is 0, 1, 2, 3 or 4 and E is C_{1-6} alkyl, C_{3-7} cycloalkyl (optionally substituted by one or more substituents independently selected from halogen, hydroxy, oxo, C_{1-6} alkyl, cyano, CF_3 , OCF_3 , C_{1-6} alkoxy and C_{1-6} alkanoyl), or aryl (optionally substituted by one or more substituents independently selected from halogen, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl, and C_{1-6} alkoxy);

or



wherein A is oxygen or sulfur, D is $-(CH_2)_t-$, $-(CH_2)_tO-$ or $-O(CH_2)_t-$, wherein t is 0, 1, 2, 3 or 4 and E is C_{1-6} alkyl, C_{3-7} cycloalkyl (optionally substituted by one or more substituents independently selected from halogen, hydroxy, oxo, C_{1-6} alkyl, cyano, CF_3 , OCF_3 , C_{1-6} alkoxy and C_{1-6} alkanoyl), or aryl (optionally substituted by one or more substituents independently selected from halogen, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl, and C_{1-6} alkoxy).


6. (currently amended) A compound as claimed in claim 1 ~~any of claims 1-5~~, wherein E is a 5- to 7- membered monocyclic aromatic ring wherein one or more of the carbon atoms in the ring is optionally replaced by a heteroatom independently selected from nitrogen, oxygen and sulfur, wherein the ring is optionally substituted by one or more substituents independently selected from oxo, halogen, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl, and C_{1-6} alkoxy; or E is a 9- to 10- membered bicyclic aromatic ring, wherein one or more of the carbon atoms in the ring is optionally replaced by a heteroatom independently selected from nitrogen, oxygen and sulfur, wherein the ring is optionally substituted by one or more substituents independently selected from oxo, halogen, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl, and C_{1-6} alkoxy.

7. (currently amended) A compound as claimed in claim 1 ~~any of claims 1-5~~, wherein E is methylamine, ethylamine, propylamine, isopropylamine, butylamine, isobutylamine, sec-butylamine, tert-butylamine, pentylamine, neopentylamine, sec-

pentylamine, n-pentylamine, isopentylamine, tert-pentylamine, hexylamine; dimethylamine, diethylamine, dipropylamine, diisopropylamine, dibutylamine, diisobutylamine, disec-butylamine, ditert-butylamine, dipentylamine, dineopentylamine, dihexylamine, butylmethlamino, isopropylmethlamino, ethylisopropylamino, ethylmethlamino; a monoarylamino such as anilino; or a monoC₁₋₆alkyl-monoarylamino.


8. (currently amended) A compound as claimed in claim 1 ~~any of claims 1-7~~, wherein R₃ and R₄, together with the nitrogen atom to which R₃ and R₄ are attached, form a 4-6 membered monocyclic heterocyclic group optionally substituted by one or more substituents selected from oxo, halogen, C₁₋₆alkyl, cyano, CF₃, C₁₋₆alkoxy, C₁₋₆alkanoyl, aryl and arylC₁₋₆alkyl (wherein the aryl and the arylC₁₋₆alkyl are further optionally substituted by one or more halogen, oxo, C₁₋₆alkyl, cyano, CF₃, C₁₋₆alkoxy or C₁₋₆alkanoyl); or R₃ and R₄, together with the nitrogen atom to which R₂ and R₃ are attached, form a 8-10 membered bicyclic heterocyclic group optionally substituted by one or more substituents selected from oxo, halogen, C₁₋₆alkyl, cyano, CF₃, C₁₋₆alkoxy, C₁₋₆alkanoyl, aryl and arylC₁₋₆alkyl (wherein the aryl and the arylC₁₋₆alkyl are further optionally substituted by one or more halogen, oxo, C₁₋₆alkyl, cyano, CF₃, C₁₋₆alkoxy or C₁₋₆alkanoyl).

9. (original) A compound as claimed in claim 1, having a general formula (Ia):



wherein:

- R₁ is halogen, cyano, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy or haloC₁₋₆alkyl;
- m is 0, 1, 2, 3 or 4;
- X is N or CH;
- p is 1, 2, 3 or 4;
- Y is -CH₂-, -CH(C₁₋₆alkyl)- or -C(C₁₋₆alkyl)(C₁₋₆alkyl)-;
- Z is -CH₂-, -CHOH-, -CHR₆- or -CR₆R₇-, wherein R₆ and R₇ are independently halogen, cyano, C₁₋₆alkyl or C₁₋₆alkoxy;
- R₃ and R₄ are independently hydrogen, C₁₋₆alkyl, C₁₋₆alkylsulfonyl or a group having the formula (II):



wherein:


- r is 0, 1, 2, 3 or 4;
 - A is oxygen or sulfur;
 - B is a single bond or $\text{---NR}_8\text{---}$ wherein R_8 is hydrogen, C_{1-6} alkyl or aryl optionally substituted by one or more substituents independently selected from halogen, oxo, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl, and C_{1-6} alkoxy;
 - D is $\text{---(CH}_2\text{)}_t\text{---}$, $\text{---(CH}_2\text{)}_t\text{O---}$ or $\text{---O(CH}_2\text{)}_t\text{---}$, wherein t is 0, 1, 2, 3 or 4; and
 - E is C_{1-6} alkyl, halo C_{1-6} alkyl, C_{3-7} cycloalkyl (optionally substituted by one or more halogen, hydroxy, oxo, C_{1-6} alkyl, cyano, CF_3 , OCF_3 , C_{1-6} alkoxy or C_{1-6} alkanoyl), or aryl (optionally substituted by one or more substituents independently selected from halogen, oxo, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl, and C_{1-6} alkoxy); or E is $\text{---NR}_9\text{R}_{10}$ (wherein R_9 and R_{10} are independently selected from hydrogen, C_{1-6} alkyl and aryl optionally substituted by one or more substituents independently selected from halogen, oxo, C_{1-6} alkyl, CF_3 , cyano, hydroxy, C_{1-6} alkanoyl, and C_{1-6} alkoxy);
- or R_3 and R_4 , together with the nitrogen atom to which R_3 and R_4 are attached, combine to form a 3-7 membered monocyclic heterocyclic group (optionally substituted by 1 to 4 substituents, which may be the same or different, and which is selected from halogen, oxo, C_{1-6} alkyl, cyano, CF_3 , C_{1-6} alkoxy and C_{1-6} alkanoyl);
 - R_5 is independently halogen, cyano, C_{1-6} alkyl or C_{1-6} alkoxy; and
 - q is 0, 1, 2, 3 or 4.
10. (original) A compound as claimed in claim 1, which is:
- 3-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-1,3-oxazolidin-2-one;
 - N-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-N'-phenylurea;
 - N-[2-(methyloxy)phenyl]-N'-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)urea;
 - 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone;

- 2,4-dimethyl-*N*-(3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-1,3-thiazole-5-carboxamide;
- *N*-(3-{1-hydroxy-2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-2,4-dimethyl-1,3-thiazole-5-carboxamide;
- 2-fluoro-*N*-(3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)benzamide;
- 3-(3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]propyl}phenyl)-1,3-oxazolidin-2-one;
- 3-(3-{2-[(2*R*)-2-methyl-4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-1,3-oxazolidin-2-one;
- 1-methyl-3-(3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone;
- 1-(4-fluoro-3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone;
- 3-(4-fluoro-3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-1,3-oxazolidin-2-one;
- 1-(3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-2,4-imidazolidinedione;
- 1-(3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-1,3-dihydro-2*H*-imidazol-2-one;
- 1-methyl-3-(3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-1,3-dihydro-2*H*-imidazol-2-one;
- 4,4-dimethyl-1-(3-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone;

or a pharmaceutically acceptable salt thereof.


11. (original) A process for the preparation of a compound as claimed in claim 1, which process comprises:

(a) converting a compound of formula (III):



wherein R_1 , m , X , R_2 , n , W , p , Y , Z , R_5 and q are as defined in claim 1; or


(b) for a compound of formula (I) wherein Y and Z form a cyclopropylene group,




converting a compound of formula (IV):

wherein R_1 , m , X , R_2 , n , W , p , R_3 , R_4 and R_5 and q are as defined in claim 1; or

(c) reacting a compound of formula (V):




wherein R_1 , m , X , R_2 , n , W , p , Y , Z , R_5 and q are as defined in claim 1, and L is a leaving group, with a compound of formula (VI):




wherein R_3 and R_4 are as defined in claim 1; or

(d) reacting a compound of formula (VII):




wherein R_1 , m , X , R_2 and n are as defined in claim 1, with a compound of formula (VIII):




wherein W , p , Y , Z , R_5 , q , R_3 and R_4 are as defined in claim 1, and L is a leaving group; or

(e) for a compound of formula (I) wherein Z is $-\text{CH}(\text{OH})$, reacting a compound of formula (VII) as defined in step (d) with a compound of formula (XIII):




wherein W , p , Y , Z , R_5 , q , R_3 and R_4 are as defined in claim 1; or

(f) for a compound of formula (I) wherein Y and Z form a C_{3-7} cycloalkylene group, reacting a compound of formula (VII) as defined above with a compound of formula (XIV):



wherein R_5 , R_2 , R_3 and q are as defined in claim 1 and a is 0, 1, 2, 3 or 4; or

(g) for a compound of formula (I) wherein the group W or Y attached to the nitrogen in the piperazine group in formula (I) is CH₂ or CH(C₁₋₆alkyl), reacting a compound of formula (VII) as defined above with a compound of formula (XV):



(XV)

wherein R₃, R₄, R₅, q, Z, Y and W are as defined in claim 1 and b is 0, 1 or 2 and Q is hydrogen or C₁₋₆alkyl;

and thereafter optionally for any of steps (a) to (g):

- removing any protecting groups and/or
- converting a compound of formula (I) into another compound of formula (I) and/or
- forming a pharmaceutically acceptable salt.

12. (cancelled)

13. (cancelled)

14. (cancelled)

15. (currently amended) A method of treatment of a CNS disorder in a mammal ~~including a human~~, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound as claimed in claim 1 ~~any of claims 1-10~~.

16. (original) A method as claimed in claim 15, wherein the disorder is depression or anxiety.

17. (cancelled)

18. (cancelled)

19. (currently amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any of claims 1-10~~, and a pharmaceutically acceptable carrier or excipient.

20. (currently amended) A process for preparing a pharmaceutical composition as defined in claim 19, the process comprising mixing a compound as claimed in claim 1 ~~any of claims 1-10~~ and a pharmaceutically acceptable carrier or excipient.